Clinical Trial Detail


Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at :

NCT ID NCT01609556
Title First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors
Acronym IMGN853-0401
Recruitment Completed
Gender both
Phase Phase I
Variant Requirements No
Sponsors ImmunoGen, Inc.
Age Groups: senior | adult
Covered Countries USA | CAN

Facility Status City State Zip Country Details
University of Kansas Medical Center Research Institute Fairway Kansas 66205 United States Details
Massachusetts General Hospital Boston Massachusetts 02062 United States Details
Dana Farber Cancer Institute Boston Massachusetts 02115 United States Details
Barbara Ann Karmanos Cancer Institute Detroit Michigan 48201 United States Details
Memorial Sloan Kettering Cancer Center New York New York 10065 United States Details
Ohio State University Columbus Ohio 43210 United States Details
University of Oklahoma Stephenson Cancer Center Oklahoma City Oklahoma 73104 United States Details
Fox Chase Cancer Center Philadelphia Pennsylvania 19111 United States Details
Sarah Cannon Research Institute Nashville Tennessee 37203 United States Details
CTRC at the University of Texas Health Science Center San Antonio Texas 78229 United States Details
Princess Margaret Hospital Toronto Ontario M5G 2M9 Canada Details
McGill University Health Centre Montreal Quebec H4A3J1 Canada Details
*Shaded cells indicate that there was no data available from for the field